VDYNE secures funding for studies of tricuspid valve replacement device


VDYNE has announced today that it has secured a US$21 million Series C financing, proceeds of which will fund first-in-human studies of its tricuspid valve replacement device and delivery system. The financing round was supported by existing investors, including Jean Boulle Medtech, together with significant participation from a large, global medical device company.

VDYNE’s technology addresses tricuspid valve regurgitation, a condition whereby the heart can become enlarged due to impaired functionality of the tricuspid valve. The company’s novel valve replacement and minimally invasive delivery system enables the treatment of a broad range of tricuspid anatomies. VDYNE’s unique system delivers a prosthetic valve via a transfemoral catheter, and is completely repositionable and retrievable, the company said in a press release.

VDYNE is nearing completion of requisite pre-clinical studies and the proceeds from the financing will support the company’s first-in-human feasibility studies which are expected to commence in the first half 2021.

“The financing is a significant milestone for VDYNE and we warmly welcome a large, global medical device company to our investor base.  We are moving very quickly in our pre-clinical efforts and are looking forward to the commencement of human feasibility studies in the new year” commented Jean Raymond Boulle II, director of both VDYNE and Jean Boulle MedTech.


Please enter your comment!
Please enter your name here